Content area

|
|

Pyoderma gangraenosum

Forfatter(e)

Ewa Anna Burian1, Tonny Karlsmark1, 2, Karsten Fogh3 & Rikke Bech3

1) Dermato-Venerologisk Afdeling og Videncenter for Sårheling, Københavns Universitetshospital – Bispebjerg Hospital, 2) Institut for Klinisk Medicin, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet, 3) Hud- og Kønssygdomme, Aarhus Universitetshospital

Ugeskr Læger 2021;183:V12200949

Reference: 
UgeskrLæger 2021;183:V12200949
Pyoderma gangrenosum

Ewa Anna Burian, Tonny Karlsmark, Karsten Fogh & Rikke Bech

Ugeskr Læger 2021;183:V12200949

Pyoderma gangrenosum is a diagnostic and therapeutic challenge. A misdiagnosis or delayed diagnosis can lead to increased morbidity and death. A fast workup and initiation of treatment is essential. In this review, we present new diagnostic criteria, which can ease the diagnosis, and we summarise the evidence of different treatment modalities. The evidence points towards local immunosuppressive treatment in mild disease, supplemented by systemic glucorticosteroids, ciclosporin or tumour necrosis factor-alpha inhibitors in severe cases. Other biologics are emerging.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Kamaran Shorsh | 24/09
2 kommentarer
af Julius Vindbjerg Nissen | 24/09
4 kommentarer
af Carsten Anker Edmund | 24/09
26 kommentarer
af Helle Lone Jensen | 23/09
1 Kommentar
af Martin Gottliebsen | 21/09
2 kommentarer
af Bente Ulla Rasmusson | 20/09
1 Kommentar
af Carsten Reidies Bjarkam | 18/09
1 Kommentar